Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

by Minoryx Therapeutics

Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective PPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-AL...

Read more

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

by Minoryx Therapeutics

Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adr...

Read more

New research front to tackle Friedreich’s Ataxia

by IRB Barcelona - Instituto de Investigación Biomédica

IRB Barcelona starts a project with the long-term goal to achieve an injectable frataxin treatment able to reach the brain. Frataxin is the protein that is reduced in those affected by this rare and d...

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream